http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016097830-A4
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9050eaedf05c427b6ee592ca513dde7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0385204e80a801024ef6973767dd3ea4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2015-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_223d1c3667748cac78e0b44839b4c230 |
| publicationDate | 2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2016097830-A4 |
| titleOfInvention | Treatment of ebola through electromagnetically chemical infusion, using a newly adaptive language of bio-signaling cellular communications |
| abstract | Solar sonic technologies have perfected the science of electromagnically biochemical intracellular and pathogenic communication and signaling to the extent that can affect intracellular and pathogenic programming signaling, pathogenic commumcation and manipulation leading to homeostasis or apoptosis, This solar sonic technology invention is related to compositions and methods directed to a novel species of human Ebola (h Ebola) virus. The said solar sonic technology grantees to stop the Ebola virus by systematically targeting key enzyme within the virus. The death of a virus can be prompted by various electromagnetic bio-chemical communications and electrochemical pathogenic bio-communications in order to block the entry of Ebola virus into the cells and in order to dominate viral protein in both of the Ebola and Marburg filoviruses. This invention relates to a medical device programs that contain electromagnetic frequency waves of highly proprietary resonance signature emitted by cloning-resonator that gives an imaginary electromagnetic signature of a virus, a pathogen or any other organism of an identical biological structure. Insofar, this medical device will analyze the resonance signature of all healthy and viral cells, and all pathogens alike, Once the biological analyzes is vitally completed, (he viral process of intracellular and pathogenic bio-signaling communications will then begin. The final results of such communications at this very point in time are to cither attempt to convert; viral cells lo healthy cells or to begin eradication. The method of treatment of the virus also comprises steps of catheterization of the arterial vessel that feeds viral point of entry and trans -catheter administration of therapeutic pharmacological agents, which are pharmaceutically acceptable. This carries with it other simultaneous applications of approved pharmaceutical and antiviral agents on to viral point of entry as dictated by the solar sonic medical device. All toxic components will undergo a form of physiological/ genetic/ reverse engineering and all potential pharmaceutical toxicity will be chemically reformulated and rccondensed to swiftly penetrate viral cells and lead to gradual eradication, without affecting healthy cells, blood components or other internal organs. The procedure does not devastate biological sub-structures of human physiology as in the case of conventional hardcore pharmaceutical antiviral drugs. The invention also relates to the use of pharmacological multi-combination compositions and their chemical equivalents such as phytocannabinoids as a prophylactic agent or in the treatment of viral infections. The phytocannabinoids are safely used in combination with other solar sonic antiviral treatment methods like immunotoxins; these are anti body-toxins that rely on intracellular toxin action to kill target cells. Thereof the treatment of deadly viral infections by reversing pathogenic environment systematically paves the way for its eradication within viral cells preferably, at a dose of 10 - 100 mg/kg. The pharmacological mulii - combination composition may be gradually given in combination with antiviral agent, in conjunction with all other pharmacological agents. The invention also relates to microparticles that may be used for antigen delivery and vaccine immunization strategies. |
| priorityDate | 2014-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 485.